Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX - Get Free Report) EVP Ourania Tatsis sold 1,500 shares of the stock in a transaction that occurred on Friday, February 13th. The shares were sold at an average price of $499.99, for a total transaction of $749,985.00. Following the sale, the executive vice president owned 46,132 shares in the company,

I believe Vertex Pharmaceuticals Incorporated's bull run has come to an end. There's a divergence between its stock price growth over the past 5 months and the performance of Journavx and the cystic fibrosis franchise. So, in Q4, Trikafta+Kaftrio sales declined 3.1% quarter-on-quarter to about $2.57 billion, missing my "base case" scenario by $45 million.

Grange Capital LLC acquired a new stake in Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 3,554 shares of the pharmaceutical company's stock, valued at approximately $1,392,000. Vertex Pharmaceuticals makes up 1.3% of Grange Capital LLC's

Vertex Pharmaceuticals is the leader in cystic fibrosis treatment. The company has also expanded into other areas in recent years, winning approval for two new drugs.

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in TD Cowen's 46th Annual Health Care Conference. Reshma Kewalramani, President and Chief Executive Officer will participate in a fireside chat on Tuesday, March 3, 2026, at 9:10 a.m. ET. A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com, in the "Investors" section under the "News and Events" page. A replay of the conference webcast.

Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Vertex Q4 earnings miss estimates, but revenues top forecasts on strong CF sales and momentum from new launches like Alyftrek, Casgevy and Journavx.

Vertex Pharmaceuticals shares dipped 1.24% in after-hours trading Thursday despite reporting a 10% rise in fourth-quarter revenue to $3.19 billion.

Vertex Pharmaceuticals Incorporated (VRTX) Q4 2025 Earnings Call Transcript

Although the revenue and EPS for Vertex (VRTX) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.